The study The Platelet Receptor Inhibition in Ischemic Syndrome Management PRISM was designed to test the role of platelets in ACS, as well as the potential benefit of statins on the rate of cardiac events in 1,616 patients in a retrospective analysis.
El estudio The Platelet Receptor Inhibition in Ischemic Syndrome Management PRISM fue delineado para testar el papel de las plaquetas en las SCA, como también el potencial beneficioso de las estatinas en la tasa de eventos cardíacos en 1.616 pacientes, en un análisis retrospectivo.
A administração de estatinas associou-se à redução da taxa de eventos Razão de Chances [OR] de 0,49, que foi estatisticamente significativa.